EU approves Ngenla in growth hormone deficient children – Pfizer + OPKO Health
Pfizer and OPKO Health announced that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone Ngenla (somatrogon), a once-weekly injection to treat… read more.